The range is powered by NanoCeLiD technology

Emcutix Biopharmaceuticals, a wholly-owned subsidiary of Emcure Pharmaceuticals announced the launch of the new AquaOat range, powered by NanoCeLiD technology. This innovative formula harnesses advanced nanotechnology and lipid chemistry to optimise ceramide penetration into deeper layers of the skin, with soothing benefits of colloidal oatmeal which is a feature distinct from conventional formulations. AquaOat is designed to address the unmet needs of patients suffering from eczema, including atopic dermatitis, contact dermatitis, and urticaria etc.

"With the revamped AquaOat range, we are proud to introduce a true breakthrough in dermatology,
bringing a unique clinically advanced lipid encapsulated nano-ceramide plus colloidal oatmeal
formulation. Our goal is to empower dermatologists and patients with science-driven solutions that
deliver skin barrier repair and long-term relief,” said Sathya Narayanan, CEO, Emcutix
Biopharmaceuticals Ltd.

Designed to cater to diverse skin needs, each product in the AquaOat portfolio is formulated to
restore and repair the skin barrier while delivering soothing and hydrating effects. The range
includes a lotion, cream, hydrating face cleanser, and syndet bar. Hypoallergenic, non-comedogenic
and free from sulphates and parabens, this dermatologist-recommended product portfolio will be
available across from November 2025.